Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Prostate Cancer Symposium  An Educational Initiative for Patients and Healthcare Professionals  October 6, 2009  An Educational Initiative for Patients.

Similar presentations


Presentation on theme: "The Prostate Cancer Symposium  An Educational Initiative for Patients and Healthcare Professionals  October 6, 2009  An Educational Initiative for Patients."— Presentation transcript:

1 The Prostate Cancer Symposium  An Educational Initiative for Patients and Healthcare Professionals  October 6, 2009  An Educational Initiative for Patients and Healthcare Professionals  October 6, 2009

2 Concept  Provide access to information and thought leaders to promote best standards of care  dual-track format to maximize interaction  Provide a faculty of world-class clinicians and researchers who set the standards of care  Provide access to information and thought leaders to promote best standards of care  dual-track format to maximize interaction  Provide a faculty of world-class clinicians and researchers who set the standards of care

3 Meeting Objectives  Patients:  understand role of biomarkers of diagnosis/progression  describe current treatments and emerging drug protocols  discuss the importance of effective patient/doctor dialogues  Professionals:  identify best standards of care  Define the impact of treatment on co-morbid conditions  Discuss the advances in therapeutic and drug protocols  Describe the appropriate use of novel therapies  Evaluate the information’s applicability to practice management  Patients:  understand role of biomarkers of diagnosis/progression  describe current treatments and emerging drug protocols  discuss the importance of effective patient/doctor dialogues  Professionals:  identify best standards of care  Define the impact of treatment on co-morbid conditions  Discuss the advances in therapeutic and drug protocols  Describe the appropriate use of novel therapies  Evaluate the information’s applicability to practice management

4 Registered Attendance  Patients/spouses, Advocates  Targeted - 300; Actual (on-site):  41% Advocates; 32% Patients; 6% Spouses/Partners; 21% Family/Caregivers  follow-on distribution - 164:  29% Advocates; 37% Patients; 18% Spouses/Partners; 16% Family/Caregivers  Professionals  Doctors: Targeted - 100; Actual - 20 (on-site):  Medoncs - 6  Radoncs - 2  Primary Care - 12  Nurses, Public Health Staff; Industry:  Targeted - 20; Actual - 17 (on-site)  follow-on distribution - 38:  Urologists -7; RadOncs - 3; MedOncs - 9; NP/PAs - 8; Medical Centers/Public health agencies - 11  Patients/spouses, Advocates  Targeted - 300; Actual (on-site):  41% Advocates; 32% Patients; 6% Spouses/Partners; 21% Family/Caregivers  follow-on distribution - 164:  29% Advocates; 37% Patients; 18% Spouses/Partners; 16% Family/Caregivers  Professionals  Doctors: Targeted - 100; Actual - 20 (on-site):  Medoncs - 6  Radoncs - 2  Primary Care - 12  Nurses, Public Health Staff; Industry:  Targeted - 20; Actual - 17 (on-site)  follow-on distribution - 38:  Urologists -7; RadOncs - 3; MedOncs - 9; NP/PAs - 8; Medical Centers/Public health agencies - 11

5 Patient Disease Stages  Primary Therapy:  Surgery - 42%; Radiation - 27%; Active Surveillance - 27%; Drug therapy - 4%  Disease progression from primary therapy:  35% - yes; 64% - no; 1% - not sure  Current Therapy:  Not currently being treated - 82%  Hormonal therapy - 8%  Chemotherapy - 8%  Complementary/Alternative medicine - 2%  Previous or current Androgen Deprivation Therapy - 29%  Primary Therapy:  Surgery - 42%; Radiation - 27%; Active Surveillance - 27%; Drug therapy - 4%  Disease progression from primary therapy:  35% - yes; 64% - no; 1% - not sure  Current Therapy:  Not currently being treated - 82%  Hormonal therapy - 8%  Chemotherapy - 8%  Complementary/Alternative medicine - 2%  Previous or current Androgen Deprivation Therapy - 29%

6 Faculty Comments  Went well for a first meeting  Ian Thompson  Captured a heterogeneous audience  Natasha Kyprianou  Develop a “Clinical Trials” program  Tia Higano; Dan Petrylak  Offer as a regional format  Brian Stone (multiple comments)  Truly excellent conference...great response from both sides of the aisle  Andrew Salner  Went well for a first meeting  Ian Thompson  Captured a heterogeneous audience  Natasha Kyprianou  Develop a “Clinical Trials” program  Tia Higano; Dan Petrylak  Offer as a regional format  Brian Stone (multiple comments)  Truly excellent conference...great response from both sides of the aisle  Andrew Salner

7 On-going Concerns  “Lack of educational efforts”  “Will screening be part of healthcare reform”  “...men of color MUST take care of themselves”  “the quality of the faculty was over the top”  “more time for advanced disease needed”  “Lack of educational efforts”  “Will screening be part of healthcare reform”  “...men of color MUST take care of themselves”  “the quality of the faculty was over the top”  “more time for advanced disease needed”

8 Listening to the Audience: ARS initiative

9 PSA Controversy  Patient/Professional divergences  Lack of clear-cut risk communications  Risk of advanced stage first diagnosis  Hidden impact on co-morbid conditions  Patient/Professional divergences  Lack of clear-cut risk communications  Risk of advanced stage first diagnosis  Hidden impact on co-morbid conditions

10 Clinical Trials Dichotomy  Dialogue Issues  Need for actionable patient information  Dialogue Issues  Need for actionable patient information

11 Understanding the Barriers  Need to deliver actionable professional info  Empower the patient to access trials  Need to deliver actionable professional info  Empower the patient to access trials

12 Leveraging Awareness  Heighten drug knowledge for patients and professionals

13 Promote Dialogue  Breaking down the barriers to communication

14 The Prostate Net Patient Site Traffic Stats  Traffic since inception September 1996: 5.6 million visits  average 7,528 visits/month; average page views/visit – 5.73  Monthly Traffic 2009 vs. 2008: up 12.3%  Traffic source by category/domain:  US patient/family – 70.30%  US commercial organizations  US educational/healthcare/non-profit  US Government/military  Foreign domains  Traffic since inception September 1996: 5.6 million visits  average 7,528 visits/month; average page views/visit – 5.73  Monthly Traffic 2009 vs. 2008: up 12.3%  Traffic source by category/domain:  US patient/family – 70.30%  US commercial organizations  US educational/healthcare/non-profit  US Government/military  Foreign domains

15 Enhancing Awareness

16 Delivering Information Committed Sites for 2010 May 15 - Rutgers School of Public Administration: Prostate Cancer Educational Symposium June 19 - Lombardi Cancer Center: Town Hall on Prostate Cancer July 17 - Clark Atlanta University Clinical Cancer Research Center August 4 - 7: Prostate Cancer Foundation of Australia: Prostate Cancer Symposium August 28 - University of Florida Prostate Cancer Symposium September 11 - Northwestern (Chicago) Prostate SPORE: Pca and Community Outreach October - The Prostate Net: Prostate Cancer Symposium

17 Feedback Mechanisms  TPN Website archive of Symposium presentations  Structured access to information and ARS  “Survey Monkey” to build information cadre  Ability to probe for actionable data  Continuing dissemination/response network  TPN Website archive of Symposium presentations  Structured access to information and ARS  “Survey Monkey” to build information cadre  Ability to probe for actionable data  Continuing dissemination/response network

18 Thank You!


Download ppt "The Prostate Cancer Symposium  An Educational Initiative for Patients and Healthcare Professionals  October 6, 2009  An Educational Initiative for Patients."

Similar presentations


Ads by Google